Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LJPC

La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis

La Jolla Pharmaceutical logo

About La Jolla Pharmaceutical Stock (NASDAQ:LJPC)

Key Stats

Today's Range
N/A
50-Day Range
$3.12
$6.22
52-Week Range
N/A
Volume
66,708 shs
Average Volume
158,476 shs
Market Capitalization
$155.11 million
P/E Ratio
51.84
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Stock News Headlines

A “Thank You Gift” From Pres. Trump - Genius
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
See More Headlines

LJPC Stock Analysis - Frequently Asked Questions

La Jolla Pharmaceutical (NASDAQ:LJPC) posted its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.16. The biopharmaceutical company had revenue of $10.43 million for the quarter, compared to analysts' expectations of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%.

Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
5/16/2022
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:LJPC
Employees
61
Year Founded
N/A

Profitability

Net Income
$19.66 million
Pretax Margin
8.64%

Debt

Sales & Book Value

Annual Sales
$75.72 million
Book Value
($2.94) per share

Miscellaneous

Free Float
15,885,000
Market Cap
$155.11 million
Optionable
Optionable
Beta
2.39

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LJPC) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners